Glucose-6-Phosphate Dehydrogenase Deficiency and Coronavirus Disease 2019

Ariel Israel; Matitiahu Berkovitch; Eugene Merzon; Avivit Golan-Cohen; Ilan Green; Eytan Ruppin; Shlomo Vinker; Eli Magen

doi:10.1093/cid/ciad348

Glucose-6-Phosphate Dehydrogenase Deficiency and Coronavirus Disease 2019

Clin Infect Dis. 2023 Oct 5;77(7):972-975. doi: 10.1093/cid/ciad348.

Authors

Ariel Israel^{1

2}, Matitiahu Berkovitch^{2

3}, Eugene Merzon^{1

4}, Avivit Golan-Cohen^{1

2}, Ilan Green^{1

2}, Eytan Ruppin⁵, Shlomo Vinker^{1

2}, Eli Magen^{1

6}

Affiliations

¹ Leumit Research Institute and Department of Family Medicine, Leumit Health Services, Tel Aviv-Yafo, Israel.
² Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel.
³ Clinical Pharmacology and Toxicology Unit, Shamir Medical Center, Zerifin, Israel.
⁴ Adelson School of Medicine, Ariel University, Ariel, Israel.
⁵ Cancer Data Science Laboratory, National Cancer Institute, Bethesda, Maryland, USA.
⁶ Medicine A Department, Assuta Ashdod University Hospital Faculty of Health Sciences, Ben-Gurion University, Beer-Sheba, Israel.

PMID: 37282346
PMCID: PMC10552581 (available on 2024-06-07)
DOI: 10.1093/cid/ciad348

Abstract

In this cohort study conducted in a national healthcare organization in Israel, we found that individuals with glucose-6-phosphate dehydrogenase deficiency had an increased risk of coronavirus disease 2019 (COVID-19) infection and severity, with higher rates of hospitalization and diagnosed long COVID.

Keywords: COVID-19; G6PD deficiency; glucose-6-phosphate dehydrogenase.

Publication types

Research Support, N.I.H., Intramural

MeSH terms

COVID-19* / genetics
Cohort Studies
Glucosephosphate Dehydrogenase Deficiency* / complications
Glucosephosphate Dehydrogenase Deficiency* / diagnosis
Glucosephosphate Dehydrogenase Deficiency* / epidemiology
Glucosephosphate Dehydrogenase* / genetics
Humans
Israel / epidemiology
Post-Acute COVID-19 Syndrome

Substances

Glucosephosphate Dehydrogenase